Zhaoke Ophthalmology Begins Phase III Trial for Innovative Dry Eye Treatment

Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an update.

Zhaoke Ophthalmology Limited has announced the enrollment of the first patient in a Phase III clinical trial for its CsA Ophthalmic Gel, aimed at treating moderate to severe dry eye disease. This trial, involving 360 patients across 25 centers, follows regulatory approval for an Investigational New Drug application. The CsA Ophthalmic Gel, a novel formulation with improved pharmacokinetic profiles, is expected to enhance patient compliance and quality of life by offering a once-daily application with a rapid onset of action, potentially strengthening the company’s position in the expanding dry eye disease market.

More about Zhaoke Ophthalmology Ltd.

Zhaoke Ophthalmology Limited is a company focused on developing innovative ophthalmic drugs, particularly in China. Their primary product is the CsA Ophthalmic Gel, designed for treating moderate to severe dry eye disease (DED). The company is positioned in the growing DED market, which is expected to expand significantly in China and globally.

YTD Price Performance: 25.00%

Average Trading Volume: 2,641,171

Technical Sentiment Signal: Buy

Current Market Cap: HK$841.1M

For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.